# A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

> **NCT06698016** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nemtabrutinib
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT06698016
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-25
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698016, "A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06698016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*